If you have been reading about GHRH analog and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-01-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Amino acid length | 44 residues | Matches the native peptide backbone |
| Molecular weight | Approximately 5135 Da | Calculated from the peptide sequence |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
| Primary studied use | Visceral fat reduction | Investigated in HIV-associated lipodystrophy |
During the Qing dynasty, China opened itself to foreign trade under the Canton System through the port of Guangzhou (Canton), with traders from the East India Company visiting the port by the 1690s. Due to the growing British demand for Chinese tea and the Chinese Emperor's lack of interest in British commodities other than silver, British traders resorted to trade in opium as a high-value commodity for which China was not self-sufficient. The English traders had been purchasing small amounts of opium from India for trade since Ralph Fitch first visited in the mid-16th century. Trade in opium was standardized, with production of balls of raw opium, 1.1–1.6 kg (2.4–3.5 lb), 30% water content, wrapped in poppy leaves and petals, and shipped in chests of 60–65 kg (132–143 lb) (one picul). Chests of opium were sold in auctions in Calcutta with the understanding that the independent purchasers would then smuggle it into China. China had a positive balance sheet in trading with the British, which led to a decrease of the British silver stocks. Therefore, the British tried to encourage Chinese opium use to enhance their balance, and they delivered it from Indian provinces under British control. In India, its cultivation, as well as the manufacture and traffic to China, were subject to the British East India Company (BEIC), as a strict monopoly of the British government. There was an extensive and complicated system of BEIC agencies involved in the supervision and management of opium production and distribution in India.
=== Examples === 1 IU of rhEGF is defined as the potency of 0.001 μg of a rhEGF in the "91/530" standard vial. One manufacturer reports that its rhEGF is 1.4 times as potent as the 91/530 standard. 12.5 IU of oxytocin is defined as the potency of 21 μg of pure peptide in the "76/575" standard vial. Before the purification of penicillin was perfected, the amounts were also described in "International Units" (and some non-international arbitrary "units" before them) to account for batch-to-batch variation. See Penicillin § Penicillin units.
These lacteals drain into the thoracic duct which empties into the venous blood at the junction of the left jugular and left subclavian veins on the lower left hand side of the neck. This means that the fat-soluble products of digestion are discharged directly into the general circulation, without first passing through the liver, unlike all other digestion products. The reason for this peculiarity is unknown.
Sources: en.wikipedia.org
A substance that has been tested in a laboratory and has gotten approval from the U.S. Food and Drug Administration (FDA) to be tested in people. A drug may be approved by the FDA for use in one disease or condition but be considered investigational in other diseases or conditions. Also called experimental drug. (NCI) A pharmaceutical form of an active ingredient or placebo being tested or used as a reference in a clinical trial, including a product with a marketing authorization when used or assembled (formulated or packaged) in a way different from the approved form, or when used for an unapproved indication, or when used to gain further information about an approved use. (ICH E6) Investigational New Drug
=== Religion === Galloway has been outspoken in support of religious liberties. Though he has long stated that his religious beliefs are a private matter, Galloway was raised, and in 2016, said that he was a Roman Catholic Christian. In a 2013 interview, Galloway sparked controversy for saying as a Roman Catholic, he would not feel safe in an independent Scotland given the historically bigoted views harboured by many Scottish nationalists towards Catholics. At a 2012 rally, he said: "We stand for justice and haqq" and "A Muslim is somebody who is not afraid of earthly power but who fears only the Judgment Day. I'm ready for that, I'm working for that and it's the only thing I fear." In April 2012 Jemima Khan claimed Galloway had converted to Islam around 2000 and that his shahadah was performed in Kilburn, London. Galloway denied the claims, saying: "I have never attended any such ceremony in Kilburn, Karachi or Kathmandu. It is simply and categorically untrue." He went on to reiterate his position that religious beliefs are a "personal matter". His marriages to Dr Abu-Zayyad in 1994 and Rima Husseini in 2007 both took place in Muslim ceremonies. His wife since 2012, Putri Gayatri Pertiwi, is also Muslim. In March 2024, Galloway was sworn-in as an MP holding a copy of the Bible. In a Good Morning Britain interview, in April of the same year, Galloway stated he was "a practicing Roman Catholic".
=== Types of toxicity === Acute toxicity occurs over hours or a few days. Chronic toxicity results from adult daily intakes greater than 25,000 IU for 6 years or longer and more than 100,000 IU for 6 months or longer.
Sources: en.wikipedia.org
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.
The synthetic peptide incorporates modifications that slow enzymatic breakdown in circulation. Native growth hormone-releasing hormone is short-lived, whereas the analog is designed for greater stability. The core amino acid backbone is largely retained.
The main studied application is reduction of excess visceral abdominal fat in HIV-associated lipodystrophy. Research has measured fat changes through imaging. Findings concern fat distribution rather than overall body weight.
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.